Literature DB >> 23465040

Cerebrospinal fluid and urinary biomarkers in multiple sclerosis.

R Dobson1, J Topping, A Davis, E Thompson, G Giovannoni.   

Abstract

OBJECTIVES: Biomarkers with the potential for longitudinal measurements are needed in multiple sclerosis (MS). Urine is easy to collect, and repeated sampling is possible.
METHODS: 39 paired CSF and urine samples were taken. Oligoclonal bands (OCBs) were measured in CSF. Kappa and lambda free light chain (FLC), neopterin and ubiquitin C-terminal hydrolase-L1 (UCHL1) were measured in CSF and urine.
RESULTS: 16/39 samples had OCBs unique to the CSF. CSF FLC levels (P < 0.0001) were higher in OCB-positive subjects, with no difference in urinary FLC. CSF and urinary FLC did not correlate. There were a significant correlation between total CSF FLC and CSF neopterin in MS samples (correlation coefficient = 0.588, P = 0.016) and a strong correlation between CSF lambda FLC and CSF neopterin in MS samples (correlation coefficient = 0.875, P < 0.001). There was a strong correlation between urinary neopterin/creatinine levels and urinary total FLC/protein levels (correlation coefficient = 0.452, P = 0.004). Only three CSF samples (8%) had detectable levels of UCHL1. 18/38 (48%) (8/15 MS and 10/23 control) urine samples had detectable levels of UCLH1.
CONCLUSIONS: This study confirms the relationship between CSF OCBs and CSF FLCs, highlighting the importance of intrathecal B- and plasma-cell activation in MS. There is a relationship between CSF FLC and CSF neopterin in MS, highlighting the multifaceted immune activation seen in MS. Correlations in the OCB-positive group highlight the multifaceted immune activation seen in MS. Further studies are required to evaluate CSF and urinary biomarkers.
© 2013 John Wiley & Sons A/S.

Entities:  

Keywords:  CSF; free light chain; neopterin; oligoclonal bands; ubiquitin C-terminal hydrolase-L1; urine

Mesh:

Substances:

Year:  2013        PMID: 23465040     DOI: 10.1111/ane.12119

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.

Authors:  Aurélien Viaccoz; François Ducray; Yannick Tholance; Gleicy Keli Barcelos; Laure Thomas-Maisonneuve; Hervé Ghesquières; David Meyronet; Isabelle Quadrio; Stéphanie Cartalat-Carel; Guy Louis-Tisserand; Emmanuel Jouanneau; Jacques Guyotat; Jérôme Honnorat; Armand Perret-Liaudet
Journal:  Neuro Oncol       Date:  2015-05-25       Impact factor: 12.300

2.  Experimental laboratory biomarkers in multiple sclerosis.

Authors:  Borros Arneth; Jörg Kraus
Journal:  Wien Med Wochenschr       Date:  2022-03-07

3.  Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.

Authors:  Morten Stilund; Mikkel Carstensen Gjelstrup; Thor Petersen; Holger Jon Møller; Peter Vestergaard Rasmussen; Tove Christensen
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

4.  Free kappa light chains in cerebrospinal fluid as a biomarker to assess risk conversion to multiple sclerosis.

Authors:  P Menéndez-Valladares; M I García-Sánchez; P Cuadri Benítez; M Lucas; M Adorna Martínez; V Carranco Galán; J L García De Veas Silva; C Bermudo Guitarte; G Izquierdo Ayuso
Journal:  Mult Scler J Exp Transl Clin       Date:  2015-12-16

Review 5.  The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Kurt-Wolfram Sühs; Hayrettin Tumani; Marie Süße; Thomas Skripuletz
Journal:  Cells       Date:  2021-11-06       Impact factor: 6.600

6.  Machine-learning based lipid mediator serum concentration patterns allow identification of multiple sclerosis patients with high accuracy.

Authors:  Jörn Lötsch; Susanne Schiffmann; Katja Schmitz; Robert Brunkhorst; Florian Lerch; Nerea Ferreiros; Sabine Wicker; Irmgard Tegeder; Gerd Geisslinger; Alfred Ultsch
Journal:  Sci Rep       Date:  2018-10-05       Impact factor: 4.379

7.  Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis.

Authors:  Tobias Monschein; Sabine Salhofer-Polanyi; Patrick Altmann; Tobias Zrzavy; Assunta Dal-Bianco; Gabriel Bsteh; Paulus Rommer; Thomas Berger; Fritz Leutmezer
Journal:  J Neurol       Date:  2020-09-14       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.